Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Discovery & Development Drug Delivery, Clinical Trials, Formulation

A Matter of Cellular Integrity

The process of normal wound healing is complex, relying on an exquisitely choreographed interaction between a variety of bioactive proteins and other factors. When wound healing goes awry, conventional “one-drug, one-target” approaches have struggled to restore the intricate balance. 

But back in the 1970s, scarless fetal wound healing was first observed following in utero surgeries as a treatment for spina bifida. The phenomenon has been attributed to the numerous growth factors and cytokines secreted by the amnion epithelial cell layer of the placenta; notably, fetal skin contains a higher ratio of collagen type III to collagen type I compared with adult skin. The findings pointed to powerful wound healing capabilities, and scientists soon began to investigate numerous components of the fetal environment. 

Not surprisingly, there has been significant interest in fully harnessing these healing properties for therapeutic uses. For example, Noveome Biotherapeutics is developing a novel platform biologic, ST266, as a therapeutic for diverse disease indications. ST266 is a cell-free biologic secreted by a novel population of select amnion-derived epithelial cells, which have been collected from full-term placentas that are normally discarded after birth. These cells are cultured using a proprietary method and produce many of the biological factors found in amniotic fluid that may be responsible for the remarkable healing capabilities and lack of scarring observed following in utero fetal surgery.

Here, we speak to Noveome’s Larry Brown, Executive of Research & Development/Chief Scientific Officer and Randall Rupp, Executive Vice President of Manufacturing and Development, to find out more about the clinical-stage company and its objectives.

Read the full article now

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Maryam Mahdi

Associate Editor

After finishing my degree, I envisioned a career in science communications. However, life took an unexpected turn and I ended up teaching abroad. Though the experience was amazing and I learned a great deal from it, I jumped at the opportunity to work for Texere. I'm excited to see where this new journey takes me!

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register